The Longevity of Sirtuins

di David Sinclair, Eric Verdin
Pubblicazione 2012-12-01

Clinical Evidence for Targeting NAD Therapeutically

di Dina Radenkovic, Reason, Eric Verdin
Pubblicazione 2020-09-01

Inhibition of SIRT2 Potentiates the Anti-motility Activity of Taxanes: Implications for Antineoplastic Combination Therapies

di Katiuscia Bonezzi, Dorina Belotti, Brian J. North, Carmen Ghilardi, Patrizia Borsotti, Andrea Resovi, Paolo Ubezio, Antonella Riva, Raffaella Giavazzi, Eric Verdin, Giulia Taraboletti
Pubblicazione 2012-09-01

Sialyl-LewisX Glycoantigen Is Enriched on Cells with Persistent HIV Transcription during Therapy

di Florent Colomb, Leila B. Giron, Leticia Kuri-Cervantes, Opeyemi S. Adeniji, Tongcui Ma, Harsh Dweep, Emilie Battivelli, Eric Verdin, Clovis S. Palmer, Hiroaki Tateno, Andrew V. Kossenkov, Nadia R. Roan, Michael R. Betts, Mohamed Abdel-Mohsen
Pubblicazione 2020-08-01

An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients.

di Celsa A Spina, Jenny Anderson, Nancie M Archin, Alberto Bosque, Jonathan Chan, Marylinda Famiglietti, Warner C Greene, Angela Kashuba, Sharon R Lewin, David M Margolis, Matthew Mau, Debbie Ruelas, Suha Saleh, Kotaro Shirakawa, Robert F Siliciano, Akul Singhania, Paula C Soto, Valeri H Terry, Eric Verdin, Christopher Woelk, Stacey Wooden, Sifei Xing, Vicente Planelles
Pubblicazione 2013-01-01